Nohla Therapeutics

Compiled by PlainTrial · August 8, 2026

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Nohla Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

Nohla Therapeutics: 5 sponsored US clinical trials, none currently recruiting.

Nohla Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), with 2 trials.

Nohla Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

TERMINATED Phase 2

NLA101 in Adults Receiving High Dose Chemotherapy for AML

NCT03301597

COMPLETED Phase 2

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

NCT01690520

TERMINATED Phase 1

Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01701323

COMPLETED Phase 2

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

NCT01175785

COMPLETED Phase 1

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

NCT01031368

Phase Distribution

Phase	Trial count
Phase 1	2
Phase 2	3

Therapeutic Areas

Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) 2

Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) 2

Adult Acute Myeloid Leukemia With Del(5q) 2

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities 2

Adult Acute Myeloblastic Leukemia Without Maturation (M1) 1

Adult Acute Myeloblastic Leukemia With Maturation (M2) 1

Adult Acute Monocytic Leukemia (M5b) 1

Adult Acute Monoblastic Leukemia (M5a) 1

Adult Acute Minimally Differentiated Myeloid Leukemia (M0) 1

Adult Acute Megakaryoblastic Leukemia (M7) 1

How the Nohla Therapeutics early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) (2 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Nohla Therapeutics: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Nohla Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Nohla Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

4YouandMe · 5 trials · 0% recruiting
Abbott Rapid Dx · 5 trials · 0% recruiting
Access Business Group · 5 trials · 0% recruiting
Acera Surgical · 5 trials · 20% recruiting

Sponsors with similar archive density (± trial count)

10xBio · 0% recruiting · 3 trials
22nd Century Group · 0% recruiting · 3 trials
23andMe · 0% recruiting · 6 trials
3-C Institute for Social Development · 0% recruiting · 14 trials

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Nohla Therapeutics page

5 registered trials is a research-attention snapshot, not an endorsement of Nohla Therapeutics or any single study.

None of Nohla Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) is the condition Nohla Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) trials
Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Nohla Therapeutics pipeline card: 5 registered trials from official public datasets.Report a data error.